Deal Watch: Anacor Purchase Marks Pfizer's Post-Allergan Bolt-On Strategy
Celgene pays Agios $200m up front for collaboration in immuno-oncology. Biogen inks pacts with Regenxbio and Penn to apply AAV technology to its developing gene-therapy program.
You may also be interested in...
Keeping Track: Approvals For Pfizer's Eucrisa, Vericel's Maci; Submissions From Flexion, AcelRx, Ironshore
The latest drug development news and highlights from our FDA Performance Tracker.
Pfizer agreed to acquire Anacor for roughly $5.2bn, with the expectation that its late-stage PDE4 inhibitor crisaborole, under review by FDA for the treatment of atopic dermatitis, will generate peak sales of more than $2bn.
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.